Peptide research
and menopause.

Menopause relevance

Kisspeptin neurons are the direct source of the hormonal chaos at menopause. When estrogen drops, these neurons lose their inhibitory feedback signal and become hyperactive — producing the erratic GnRH/LH surges responsible for hot flashes and night sweats. Understanding (and potentially modulating) the kisspeptin pathway is one of the most mechanistically targeted approaches to menopausal symptom research. The 2023 FDA approval of fezolinetant (an NKB receptor antagonist in the same circuit) validates this pathway clinically.

Menopause relevance

VIP neurons sit at the intersection of thermoregulation and the circadian clock — the two systems most disrupted by menopause. Research suggests that estrogen normally upregulates VIP expression in hypothalamic thermoregulatory circuits; estrogen withdrawal reduces VIP signaling, narrowing the thermoneutral zone and making women hypersensitive to small temperature changes (the proposed mechanism for hot flashes). VIP is also anti-inflammatory — relevant given that the inflammatory tone increases measurably at menopause.

Menopause relevance

Weight gain at perimenopause is driven by a combination of estrogen decline, increased insulin resistance, and reduced resting metabolic rate — the exact targets of GLP-1 receptor agonism. The STEP 1 trial was approximately 75% female and demonstrated 14.9% mean body weight reduction. Emerging research is investigating GLP-1 agonists specifically in the perimenopausal and post-menopausal metabolic context.

Menopause relevance

The SURMOUNT-1 trial (majority female cohort) showed up to 22.5% mean weight loss — greater than semaglutide in head-to-head data. GIP receptor agonism may have additional relevance at menopause: GIP receptors are expressed in bone, and early data suggests tirzepatide may have favorable effects on bone density that semaglutide does not share — important given accelerated bone loss post-menopause.

Menopause relevance

Estrogen directly regulates collagen synthesis — when estrogen declines at menopause, skin collagen drops ~30% in the first five years. GHK-Cu is one of the most studied peptides for stimulating collagen and elastin gene expression, making it a key research target for post-menopausal skin and joint health.

Menopause relevance

Hypoactive sexual desire disorder (HSDD) affects up to 40% of post-menopausal women. PT-141 (bremelanotide) is the only FDA-approved peptide specifically indicated for HSDD, working centrally via melanocortin receptors rather than peripherally — meaning it addresses desire, not just physical arousal. The RECONNECT trials enrolled both pre- and post-menopausal women.

Menopause relevance

Oxytocin levels decline at menopause and the vaginal epithelium expresses oxytocin receptors — research in post-menopausal women has investigated intranasal oxytocin for genitourinary syndrome (vaginal atrophy, dryness, dyspareunia). Beyond GSM, oxytocin's cardiovascular protective effects (via nitric oxide and anti-inflammatory action) are especially relevant given the sharp increase in women's cardiovascular risk post-menopause. The HPA-dampening effect may also address the elevated cortisol stress reactivity common in the menopausal transition.

Menopause relevance

Plasma MOTS-c levels are lower in post-menopausal women compared to pre-menopausal women at the same age, and correlate inversely with insulin resistance. The metabolic shift at menopause — increased visceral fat, reduced insulin sensitivity, elevated cardiovascular risk — maps directly onto MOTS-c's AMPK-activation research profile. Animal studies show MOTS-c administration prevents ovariectomy-induced metabolic dysfunction.

Menopause relevance

Anxiety, irritability, and mood instability are among the most reported — and most undertreated — symptoms of perimenopause and menopause. Selank's research profile in generalized anxiety disorder (without sedation or dependency) makes it a relevant research target for this population. GABAergic modulation may also address the sleep disruption common in the menopausal transition.

Menopause relevance

Cognitive changes — brain fog, word-finding difficulties, memory lapses — are reported by up to 60% of perimenopausal women. Estrogen is neuroprotective; its withdrawal accelerates the same pathways Semax targets via BDNF upregulation. The perimenopause window is now considered a critical period for brain health interventions, making BDNF-pathway compounds an active area of women's neuroscience research.

Menopause relevance

Epitalon acts on the pineal gland to restore melatonin production, which declines with age and drops further at menopause — contributing to the sleep disruption, circadian dysregulation, and hot flash-related night waking that characterize this transition. Khavinson's longitudinal studies include post-menopausal women and report reductions in age-related disease biomarkers.

Menopause relevance

Growth hormone secretion declines significantly at menopause alongside estrogen — both hormones decline in tandem and both influence body composition, bone density, and sleep architecture. Ipamorelin's selective GH pulse stimulation (without cortisol elevation) is researched as a way to partially restore GH secretory patterns. Sleep-stage GH release is particularly disrupted by menopausal sleep fragmentation.

Menopause relevance

Joint pain and musculoskeletal discomfort are among the most commonly reported — and least discussed — symptoms of menopause, affecting over 50% of women in the transition. BPC-157's preclinical data on tendon, ligament, and cartilage repair makes it a researched option for connective tissue health. GI symptoms also worsen at menopause due to estrogen's role in gut motility and the gut-brain axis.